Latest Conference Articles

November 14th 2020, 3:57pm

November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.

November 14th 2020, 3:16pm

Society for Immunotherapy of Cancer

Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer.

November 14th 2020, 11:30am

November 14, 2020 – Treatment with the novel intratumoral immuotherapy agent PVSRIPO resulted in an overall response rate of 33% among all patients with anti–PD-1 refractory melanoma.

November 13th 2020, 11:39pm

November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.

November 13th 2020, 11:39pm

Francesca Aroldi, discusses the early efficacy data with RP2 in advanced solid tumors.

November 13th 2020, 11:34pm

Daniel J. George, MD, discusses the expanding role of cabozantinib in renal cell carcinoma.

November 13th 2020, 10:44pm

November 13, 2020 – The addition of urelumab, an anti-CD137 agonist to the GVAX vaccine and nivolumab led to a 30% pathologic response rate and was associated with mild toxicity as neoadjuvant or adjuvant therapy in patients with resectable pancreatic ductal adenocarcinoma.

November 13th 2020, 9:46pm

November 13, 2020 - The combination of bempegaldesleukin and the PD-1 inhibitor nivolumab elicited a confirmed best overall response rate of 53% in efficacy-evaluable patients with metastatic melanoma.

November 13th 2020, 8:35pm

Society for Immunotherapy of Cancer

November 13, 2020 - The genetically modified herpes simplex-1 oncolytic RP2 demonstrated encouraging clinical activity and an acceptable safety profile in heavily pretreated patients with advanced solid tumors

November 13th 2020, 6:56pm

SITC Meeting

November 13, 2020 - In an effort to expand the benefit of immunotherapy to nonresponders or those who have relapsed, the novel STING agonist SB 11285 is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors in a phase 1/1b dose-escalation trial.

November 13th 2020, 2:20pm

SITC Meeting

November 13, 2020 - The addition of plasmid IL-12 pembrolizumab resulted in durable responses, as well as several complete responses, in patients with advanced melanoma who were refractory to PD-1–directed therapy.

November 12th 2020, 10:53pm

SITC Meeting

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.

November 12th 2020, 10:50pm

SITC Meeting

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

November 12th 2020, 10:47pm

SITC Meeting

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

November 12th 2020, 10:33pm

SITC Meeting

November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.

November 12th 2020, 10:21pm

SITC Meeting

November 12, 2020 - The investigational PD-L1 inhibitor cosibelimab demonstrated durable and robust responses in patients with non–small cell lung cancer and cutaneous squamous cell carcinoma.

November 12th 2020, 9:50pm

SITC Meeting

November 12, 2020 - The combination of CMP-001 intratumoral injection and pembrolizumab was found to reverse PD-1 blockade resistance and elicit durable systemic responses in patients with advanced melanoma.

November 12th 2020, 9:50pm

SITC Meeting

November 12, 2020 - Cemiplimab demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma after progression on or intolerance to hedgehog inhibitors

November 12th 2020, 9:50pm

November 12, 2020 - The first-in-class, next-generation, DuoBody-PD-L1×4-1BB bispecific antibody GEN1046 demonstrated promising early activity and an acceptable safety profile in in patients with advanced solid tumors.

November 12th 2020, 9:30pm

November 12, 2020 - AMG 757, a DLL3-directed, half-life extended bispecific T-cell engager, was shown to have a feasible adverse effect profile in patients with small cell lung cancer.